tradmap

TMDX Transmedics Group, Inc.

$66.54 +1.05%

Data as of close

Healthcare · Electromedical & Electrotherapeutic Apparatus

Transmedics Group, Inc. (TMDX) is a healthcare company in the Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $2.3 billion. Shares last traded at $66.54, 57.3% below their 52-week high. Over the past year the stock is down 51.0%. TMDX trades at a price-to-earnings ratio of 15.21, below the Electromedical & Electrotherapeutic Apparatus median of 23.44. Net profit margin is 22.7%, above the peer median of -10.0%. Revenue grew 37.1% year over year.

Market Cap
$2.3B
Shares Out
34.7M
EPS (TTM)
$3.86
P/E (TTM)*
15.21
P/S Ratio
3.45
P/B Ratio
4.45
Dividend / Share
—
Dividend Yield
—
52-Week High
$155.67
52-Week Low
$60.12
Volume (venue)
44,312
Avg Vol (3m, venue)
44,054.778

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-5.70%
1M
-16.66%
3M
-11.28%
6M
-31.38%
YTD
-45.32%
1Y
-50.96%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
31.34
SMA (50)
$81.08
SMA (200)
$94.09
Price vs SMA50
-17.93%
Price vs SMA200
-29.28%
ATR (14)
$3.45

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$668M
Net Income
$152M
Gross Margin
58.7%
Operating Margin
12.2%
Net Margin
22.7%
Return on Equity
29.3%
Return on Assets
10.4%
Current Ratio
6.62
Debt / Equity
0.11
Revenue Growth (YoY)
+37.1%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $0.41 2026-08-04
Q1 2026 $0.20 2026-05-05
Q4 2025 (derived) $2.59 2026-02-24
FY 2025 $4.87 2026-02-24
Q3 2025 $0.66 2025-10-29
Q2 2025 $0.92 2025-07-30

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Electromedical & Electrotherapeutic Apparatus peers

TMDX vs 14 industry peers (Electromedical & Electrotherapeutic Apparatus), by market cap. Data as of close

P/E vs peers
15.21 / 23.44 med
-35% discount
P/S vs peers
3.45 / 2.65 med
+30% premium
Net margin vs peers
22.7% / -10.0% med
above median
1–14 of 14
MDTMedtronic$127.0B24.283.3813.9%+2.86%
LIVNLivanova Plc$4.4B23.443.0012.8%+1.58%
ITGRInteger Holdings Corp$4.3B41.502.365.7%-0.02%
AXGNAxogen, Inc.$3.0B—11.16-12.0%+0.97%
TMDXTransmedics Group, Inc.$2.3B15.213.4522.7%+1.05%
CNMDConmed Corp$1.4B29.481.013.4%+5.20%
CBLLCeribell, Inc.$1.0B—10.15-64.7%+1.51%
INMDInmode Ltd.$867M9.242.3425.3%+3.56%
CVCapsoVision, Inc$337M———-1.32%
ELMDElectromed, Inc.$224M19.853.0415.3%-0.28%
FOCLEDAP TMS SA$161M—2.29-41.5%+2.26%
VANIVivani Medical, Inc.$99M—207.94—+0.00%
STXSStereotaxis, Inc.$88M—2.93-74.2%+2.76%
NRXSNeuraxis, INC$84M———-6.91%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.